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Objective: To formulate orally disintegrating taste masked tablets of drotaverine hydrochloride (HCl) by sublimation technique. 
Methods: Initially superdisintegrant was selected and its concentration was optimized by pre-compression and post-compression parametric 
evaluation. Camphor and menthol were used as sublimating agents alone and in combination to mask the taste of drotaverine hydrochloride. 
Prepared tablets were evaluated for physicochemical evaluation, in vitro dissolution studies and fourier transformation-infrared spectroscopy, 
differential scanning calorimetry and X-ray diffractometry studies.  
Results: The optimised formulation DCM2 prepared with a mixture of camphor and menthol was characterised by fourier transformation-infrared 
spectroscopy, differential scanning calorimetry and X-ray diffractometry studies and found no incompatibility and no major shifts were noticed.  
Conclusion: The results demonstrated that the prepared drotaverine HCl orally disintegrating tablets showed better taste masking. The present 
sublimation technique can be effectively used for taste masking and also for orally disintegrating tablets. 
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Drotaverine hydrochloride (HCl) is a benzylisoquinoline derivative, 
which causes relaxation of smooth muscle that suppresses pain 
associated with spasm caused by smooth muscle contraction. 
Drotaverine HCl is sparingly soluble drug having a very bitter taste and 
patients are reluctant to its taste when the ordinary tablet is kept on the 
tongue during swallowing. Hence, there is a poor patient compliance of 
using drotaverine HCl which necessitates the masking of its bitter taste 
during administration and improvement in its solubility and dissolution 
rate for patient compliance and improved bioavailability. 
In this technology, the disintegration step will be completed in the oral 
cavity such that dissolution can be initiated in the stomach thereby 
improving the efficacy of the drug. However, the taste of the drug plays 
a vital role in the success of this technique as the disintegration occurs 
in the mouth. In case of drotaverine, HCl simple technology of oral 
disintegrating tablet (ODT) is not suitable and technologies that are 
suitable for improving both taste and disintegration rate are necessary 
[1-4]. Earlier workers reported on taste masking of drotaverine HCl by 
using approaches like solid dispersion, a drug coating, complexation 
with polymers and coprocessing with superdisintegrants [5-8].  
There are no reports cited earlier for the applicability of ODT 
technology for drotaverine HCl. The applicability of techniques like 
sublimation and solid mixtures were tried for drugs like fisinopril, 
fenofibrate, levocetirizine dihydrochloride and itraconazole in the 
design of ODT [9-12]. Hence, in the present investigation, it is 
proposed to prepare taste masked ODT of drotaverine HCl using 
camphor and menthol as subliming agents with a disintegration time 
of less than 1 min with complete drug release in 30-60 min. 
MATERIALS AND METHODS 
Materials 
Drotaverine HCl was gifted by Biocon Ltd, Avicel PH 101, sodium 
starch glycolate were gifted by Dr. Reddy’s Labs. Camphor, Menthol, 
Croscarmellose sodium, PVP K-30, Mannitol, Talc and Magnesium 
stearate all are of analytical grade. 
Selection and optimizing super disintegrant concentration 
Drotaverine HCl tablets were prepared by wet granulation method 
using different superdisintegrants namely Avicel PH101, sodium 
starch glycolate and croscarmellose sodium and were evaluated for 
the selection and optimization of super disintegrant. 
Preparation of granules with superdisintegrant 
The required quantities of materials were weighed according to the 
formulae given in table 1. The materials are passed through sieve #40 
(aperture 425 µm ASTM). Drug was geometrically mixed with other 
excipients except lubricants until a homogeneous blend was obtained. 
Granules were prepared by using 5% w/v solution of pvp k-30 in 
isopropyl alcohol as binder solution and the wet mass was passed 
through sieve #18 (aperture 1000 µm ASTM) and dried at 40 °C. The 
dried granules were sifted through sieve #30 (aperture 600 µm ASTM). 
The dried granules were blended with talc and magnesium stearate. 
Preparation of granules with a sublimating agent 
The granules with sublimating agents as per formulae shown in table 2 
were prepared using the procedure described in the above section. 
Evaluation of granules  
The prepared granules were evaluated for flow properties like the 
angle of repose, compressibility index and Hausner’s ratio.  
Angle of repose 
It was determined by the fixed funnel and free-standing cone 
method. A powder funnel in which the end of the stem is 
perpendicular to its axis of symmetry was fixed at a given height (h) 
above the graph paper placed on a flat horizontal surface. The 
material was carefully poured through the funnel until the apex of 
the conical pile just touched the tip of the funnel [13, 14]. The radius 
(r) of the base of the pile was determined and the tangent angle of 
repose (θ) was calculated using the Eq. 1. 
……… Eq. 1 
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Table 1: Formulae of drotaverine hydrochloride orally disintegrating tablets prepared using superdisintegrants 












Talc Mannitol Total 
weight (mg) 
DX1 40 2 - - 5 1 1 51 100 
DX2 40 3 - - 5 1 1 50 100 
DX3 40 4 - - 5 1 1 49 100 
DY1 40 - 2 - 5 1 1 51 100 
DY2 40 - 3 - 5 1 1 50 100 
DY3 40 - 4 - 5 1 1 49 100 
DZ1 40 - - 2 5 1 1 51 100 
DZ2 40 - - 3 5 1 1 50 100 
DZ3 40 - - 4 5 1 1 49 100 
 









Talc Mannitol Total weight 
(mg) 
DC1 40 2 1 - 5 1 1 50 100 
DC2 40 3 1 - 5 1 1 49 100 
DC3 40 4 1 - 5 1 1 48 100 
DC4 40 4 3 - 5 1 1 46 100 
DC5 40 4 5 - 5 1 1 44 100 
DM1 40 4 - 1 5 1 1 48 100 
DM2 40 4 - 2 5 1 1 47 100 
DM3 40 4 - 3 5 1 1 46 100 
DM4 40 4 - 4 5 1 1 45 100 
DM5 40 4 - 5 5 1 1 44 100 
DM6 40 4 - 6 5 1 1 43 100 
DCM1 40 4 5 3 5 1 1 41 100 
DCM2 40 4 5 4 5 1 1 40 100 
DCM3 40 4 5 5 5 1 1 39 100 
DCM4 40 4 5 6 5 1 1 38 100 
 
Carr’s index 
Powder/granules were accurately weighed, transferred into a 100 ml 
measuring cylinder and placed on to the tapped density tester and 
subjected to USP II method i.e., 250 drops per minute with a drop height 
of 3±0.3 mm for 250 tappings. Volume (Vt) of the powder was measured 
after 500 tapings. The tapping was repeated for additional 750 times and 
volume was noted as (Vb). If the difference between the two volumes is 
less than 2 % then Vt is the final tapped density else it is repeated for 
another 1250 taps [15, 16]. It is calculated by the Eq. 2. 
 …….. Eq. 2 
Hausner ratio 
Hausner ratio is related to inter particulate friction and as such, 
could be used to predict powder flow properties. The powder with 
low interparticle friction such as coarse spheres has ratios of 
approximately 1.2, whereas more cohesive, less free-flowing 
powders such as flakes have Hausner ratio greater than 1.6 [15, 16]. 
It is calculated by using the following formula Eq. 3. 
 …………. Eq. 3 
Preparation of drotaverine HCl tablets 
The dried granules were subjected to lubrication and the blend was 
compressed into tablets on Karnavati 12 station rotary tablet 
compression machine using 8 mm concave punches. Compressed 
tablets prepared with sublimating agents were subjected to 
sublimation at 40 °C for different time points i.e. 1 h, 3 h and 5 h in a 
hot air oven. 
Evaluation of the tablets 
The compressed tablets were evaluated for general appearance, 
hardness, thickness, uniformity of weight, friability, uniformity of 
content, in vitro disintegration test, fineness of dispersion, in vitro 
dispersion, wetting time, in vitro dissolution, in vivo disintegration, 
taste evaluation and drug excipients compatibility studies. 
General appearance 
Five tablets were selected randomly and evaluated for color and 
shape. 
Hardness 
The hardness of tablets is determined by using Monsanto hardness 
tester. It is expressed in Kgcm-2
Thickness: Thickness is measured in mm using Vernier calipers and 
recorded (n=5). 
(n = 5). 
Uniformity of weight 
Twenty tablets were selected at random, weighed individually and 
average weight was calculated as per IP [12]. The mean and the 
standard deviation were determined. 
Friability test 
Friability test was carried out in Roche friabilator according to IP 
[13]. The percent loss in weight (F) was calculated by the Eq. 4. The 
limit for friability is less than 1%. 
 ……………….. Eq. 4 
Uniformity of content 
Ten tablets were taken randomly. All the tablets were crushed 
separately to a fine powder and each tablet analysed individually for 
drug content. Powder of each tablet was taken into a 100 ml 
volumetric flask. 50 ml of 0.1N HCl was added, shaken for 30 min 
and was made to volume with 0.1N HCl and filtered. 1 ml of the 
filtrate was taken into 10 ml volumetric flask and volume were made 
up to mark with 0.1N HCl. The absorbance was measured at 303 nm 
using UV spectrophotometer. Each tablet should contain not less 
than 85 % and not more than 115 % of the labelled claim [17].  
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In vitro disintegration test 
Simulated salivary fluid is prepared by dissolving 13.872 gm of 
potassium dihydrogen phosphate, 35.084 gm of disodium hydrogen 
phosphate in sufficient water and was made up to 1000 ml. Finally, 
the pH was adjusted to 6.8 with NaOH solution. The test was 
performed to ensure disintegration of tablets as per IP in the 
simulated salivary fluid at 37 °C. To be in compliance with the IP 
standards, dispersible tablets must disintegrate within 3 min [18]. 
In vitro dispersion time (with simulated salivary fluid) 
This test was performed to ensure disintegration of tablets in the 
salivary fluid, if it is to be used as an orodispersible tablet. In vitro 
dispersion time was measured by dropping a tablet in a measuring 
cylinder containing 6 ml of simulated salivary fluid of pH 6.8. Three 
tablets from each formulation were randomly selected and in vitro 
dispersion time was performed [19]. 
Wetting time 
Wetting time corresponds to the time taken for the tablet to 
disintegrate when kept motionless on the tissue paper in a petri 
dish. This method will duplicate the in vivo disintegration, as the 
tablet is motionless on the tongue. Wetting time was measured by 
placing a tablet on a piece of tissue paper folded twice and was 
placed in a small petri dish containing 6 ml of simulated saliva pH 
6.8, and the time for complete wetting was measured [20]. Five 
tablets from each batch were used. 
In vitro dissolution studies 
The release of drotaverine HCl from prepared tablets was studied in 
0.1N HCl by using USP Type II apparatus. 900 ml of 0.1N HCl solution 
was used as the dissolution medium for drug release studies. The 
paddle rotation was adjusted to 50 rpm and the bath temperature at 
37±0.5 °C was maintained throughout the dissolution test. Aliquots 
of 5 ml of the dissolution medium were withdrawn at appropriate 
time intervals (5, 10, 15, 30, 45, 60, 90 and 120 min). The volume 
withdrawn at each time interval was replaced by the same quantity 
of the fresh dissolution medium maintained at 37±0.5 °C. The 
samples were suitably diluted with 0.1N HCl solution and analyzed 
at 303 nm using UV-visible spectrophotometer against the blank. 
In vivo disintegration time and taste evaluation 
The study protocol was approved from Andhra University 
Institutional Ethics Committee vide approval No.53 dated 
05.07.2012. For in vivo disintegration test, five healthy human 
volunteers were selected. Prior to the test, all the volunteers were 
asked to rinse their mouth with distilled water [21]. Each of the five 
subjects was given a tablet. The tablets were placed on the tongue 
immediately the time was recorded. It was expressed in seconds. 
The subjects were asked to spit out the content of the oral cavity 
after tablet disintegration and rinse their mouth with distilled water. 
The swallowing of the saliva was prohibited during the test and also 
saliva was rinsed from the mouth after each measurement. Three 
trials were performed with 2 d intervals between trials [22]. The test 
results were presented as the mean value. 
Taste evaluation was done on five volunteers by using the time-
intensity method. One tablet was held in mouth and bitterness levels 
were recorded instantly at 10 secs, 30 secs and 1 min the bitterness 
levels, grittiness and numbness levels are noted and recorded. 
Drug-excipient compatibility studies 
The optimized formulations were evaluated for drug excipient 
interaction studies via differential scanning calorimetry, X-Ray 
diffractometry and Fourier transformed infrared spectroscopy.  
Differential scanning calorimetry 
DSC was performed utilizing DSC Q20 Universal V4.5A TA 
Instruments. Samples were allowed to equilibrate for 1 min and then 
heated in an atmosphere of nitrogen over a temperature range from 
0 to 300 °C. Thermograms were obtained by using TA Instruments 
universal analysis software 2000. 
X-Ray diffractometry 
The samples were recorded on X-Ray diffractometer (PW 1729, 
Philips, Amsterdam, Netherlands). XRD patterns were recorded 
using monochromatic CuKα radiation with Ni filter at a voltage of 40 
kV and a current of 30 m A between 10 ° to 80 ° 2θ values. The data 
were processed with the software Diffrac Plus V1.01. 
Fourier transformed infrared spectroscopy 
FTIR spectra can be used to detect drug-excipient interactions by 
following the shift in vibrational or stretching bands of key 
functional groups. KBr pressed pellet technique was used in the 
preparation of pellet. The resultant pellet was kept in the IR 
chamber and the IR spectra of the mixtures were recorded on a 
Bruker FTIR spectrophotometer equipped with Opus software. 
RESULTS AND DISCUSSION 
The drotaverine HCl ODT was prepared and evaluated by using the 
different superdisintegrants namely Avicel PH101, sodium starch 
glycolate and croscarmellose sodium. 
Evaluation of the granules 
The prepared granules were evaluated for their flow characteristics 
using the angle of repose, Carr’s Index and Hausner’s ratio. Though the 
values obtained are close and all are well below the desirable limits 
indicate good granule characteristics for tablet compression. The 
formulation DZ3 with 4 % croscarmellose sodium with values of angle of 
repose 20.28 and Carr’s index 7.6 has shown the lowest values among all 
the formulations. The values of angle of repose, Carr’s index and 
Hausner’s ratio of granules with sublimating agents are low indicating 
good flow characteristics. The results were mentioned in table 3 and 4. 
Selection and optimization of the superdisintegrant 
The superdisintegrants, viz., croscarmellose sodium, sodium starch 
glycolate and Avicel PH 101 were evaluated and concentration required 
in the formulations was optimized by trial and error method in which 
superdisintegrant concentration was varied from 2 to 4 % w/w of the 
total weight of the tablet. Tablets prepared with croscarmellose sodium 
at 4 % w/w shown least disintegration time. Hence 4 % w/w of 
croscarmellose sodium as the superdisintegrant was selected to further 
develop the formulations for taste masking. Further studies with 
superdisintegrant concentration above 4 % w/w were not considered 
necessary as the required lower disintegration time is attained. Further 
disintegration times may reduce with sublimating agents which form 
pores facilitating faster disintegration times. Increasing croscarmellose 
beyond 4 % may prolong disintegration times due to swelling nature of 
the polymer. The disintegration time values for different super-
disintegrant concentrations are expressed in the table 5. 
 
Table 3: Flow parameters for drotaverine HCl granules prepared using superdisintegrants 
Formulation Angle of repose (°) Carr’s index (%) Hausner’s ratio 
DX1 22.35 9.99 1.09 
DX2 20.36 8.33 1.10 
DX3 22.96 7.60 1.13 
DY1 21.57 14.2 1.08 
DY2 24.14 11.5 1.10 
DY3 22.58 10.7 1.11 
DZ1 21.52 13.7 1.15 
DZ2 21.43 11.5 1.12 
DZ3 20.28 7.6 1.08 
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Table 4: Flow parameters for drotaverine HCl granules prepared using subliming agents 
Formulation Angle of repose ( °) Carr’s index (%) Hausner’s ratio 
DC1 21.52 8.33 1.08 
DC2 20.35 7.4 1.12 
DC3 22.96 9.09 1.09 
DC4 21.57 14.2 1.08 
DC5 23.15 11.5 1.10 
DM1 23.15 10.7 1.12 
DM2 20.28 13.7 1.15 
DM3 21.43 11.5 1.13 
DM4 22.35 7.6 1.08 
DM5 20.46 9.09 1.10 
DM6 23.33 8.33 1.09 
DCM1 22.61 14.2 1.16 
DCM2 23.45 11.5 1.13 
DCM3 21.73 7.6 1.08 
DCM4 20.76 10.7 1.12 
 
Table 5: Effect of superdisintegrant concentration on the disintegration of the tablet 
Superdisintegrant* Disintegration time (secs) 
Croscarmellose sodium Sodium starch glycolate Avicel PH 101 
2 65 80 90 
3 39 62 76 
4 19 45 30 
*Percent weight based on total tablet weight 
 
Evaluation of the tablets 
The tablets prepared with different superdisintegrants were evaluated 
for hardness, frialbility, weight variation, thickness and in vitro 
disintegration time only. However all the prepared tablets with 
sublimating agents were evaluated for the general properties like 
appearance, thickness, hardness, friability, uniformity of weight, 
uniformity of content, in vitro disintegration, in vitro dispersion, 
uniformity of dispersion, wetting time, in vitro dissolution and in vivo 
disintegration and taste evaluation. The results were tabulated in table 6, 
7 and 9. 
The average hardness of all the tablets prepared was in the range of 
2-3 Kg/cm2
All the tablets prepared for evaluation of superdisintegrant disintegrated 
within 90 secs. The lowest disintegration time of 19 secs is noticed with 
formulation DZ3 having 4 % croscarmellose sodium. The results are 
shown in table 6. The results of in vitro disintegration test for tablets 
with sublimating agents varied between 4 and 10 secs indicate the 
tablets passing the compendial limit of 3 min for dispersible tablets and 
the results indicated in table 7. The disintegration time of the tablets 
from batch DC5 (camphor formulation) is 6 secs. DM6 (menthol 
formulations) showed the disintegration time of 4 secs. DCM2 
(camphor+menthol) showed the disintegration time of 4 secs. The 
formula with camphor and menthol combined as sublimating agents 
showed the least disintegration time indicating that they were suitable 
as orodispersible tablets. 
. The thickness of the tablets was in the range of 3.10 to 
3.14 mm. All the prepared tablets passed the weight variation test, 
as the % weight variation was within the pharmacopoeial limits 
i.e.±7.5 %. The percentage friability of the tablets prepared using 
superdisintegrant are shown in table 6 and that of sublimating 
agents are shown table 7. All the tablets showed values around 0.5 
%. The values are less than 1 % in all the tablets ensuring that the 
tablets were mechanically stable.  
In vitro disintegration time 
Uniformity of content 
The results of drug content uniformity are given in table 7. The 
percentage drug content present in all the batches were about 98–99 %. 
The result indicated very less deviation in drug content indicating the 
uniform mixing of the drug in the granulation during tablet preparation.  
Fineness of dispersion 
All the tablets prepared formed a uniform dispersion and passed 
through sieve #22 thereby meeting the compendial requirement. 
In vitro dispersion time 
The dispersion time of all the tablets prepared were 5 to 9 secs with 
camphor, 4 to 9 secs with menthol and 3 to 9 secs with camphor and 
menthol combination. Tablets prepared with a combination of 
menthol and camphor has shown faster dispersion and the values of 
in vitro dispersion time are given in table 7. 
Wetting time 
The wetting time values are in close range and however, the values 
varied from lowest of 3.7 secs with a DCM4 formulation to the highest 
9.6 secs for DM1. The values of the wetting time were given in table 7. 
  
Table 6: Tabletting properties of drotaverine HCl ODT (superdisintegrant evaluation) 




b In vitro disintegration timec 
DX1 2-3 0.52 101±1.45 3.10±1.02 90±0.90 
DX2 2-3 0.50 100.5±1.20 3.12±1.22 76±1.00 
DX3 2-3 0.48 97.5±1.35 3.14±1.10 30±1.32 
DY1 2-3 0.47 104±1.60 3.12±1.14 80±0.80 
DY2 2-3 0.46 101.5±1.20 3.10±1.12 62±0.10 
DY3 2-3 0.36 101±1.45 3.14±1.24 45±1.26 
DZ1 2-3 0.21 98.6±1.55 3.12±1.24 65±1.29 
DZ2 2-3 0.25 100.4±1.64 3.10±1.16 39±1.43 
DZ3 2-3 0.33 101±1.53 3.10±1.18 19±1.36 
a =mean±percent deviation (n=20); b=mean±SD (n=5); c= mean±SD (n=6) 
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Optimization of the sublimation time of exposure 
After finalizing the superdisintegrant, further tablets were made 
with sublimating agents, viz., camphor, menthol and combination of 
both camphor and menthol. The prepared granules were evaluated 
for their flow characteristics and values are given in table 4. Further, 
the tablets prepared with sublimating agents were evaluated for all 
the tabletting parameters and for taste and in vivo disintegration 
studies were given in table 7.  
The time of exposure at which the tablets subjected to sublimation 
was optimized by exposing the tablets to 40 °C for 1 h, 3 h and 5 h. 
The tablets were further subjected to in vitro disintegration test. The 
tablets that were subjected to 5 h of sublimation showed least 
disintegration time. The details are shown in table 8. 
In vitro dissolution studies 
The drug dissolution data of the tablets prepared by using camphor, 
menthol and combination of camphor and menthol are given in the 
table 9 to 11. The corresponding dissolution profiles of all the 
prepared tablets are shown in the fig. 1 to 3. The dissolution profile 
of the batch DC5 (camphor formulations) showed 102 % drug 
release in 10 min. DM6 of the menthol formulation showed 102.7 % 
release of the drug in 5 min. DCM2 of the combination formulations 
(camphor+menthol) showed drug release of 100.16% in 5 min. 
 
 
Fig. 1: Dissolution profile of the formulations DC1 to DC5 prepared using camphor 
 
 
Fig. 2: Dissolution profile of the formulations DM1 to DM6 prepared using menthol 
 




















time  (Sec) (Sec) 
In vivo 
disintegratio







DC1 2.3 3.08±1.02 0.52 101±1.45 99.25±1.22 8.61±0.90 9±1.20 9.00±1.23 8.75±0.67 Pass 
DC2 2.3 3.10±1.22 0.50 100.5±1.20 99.78±1.34 8.66±1.00 10±0.90 10.12±1.05 9.23±1.34 Pass 
DC3 2.6 3.12±1.10 0.48 97.5±1.35 99.23±1.45 6.84±1.32 7±1.23 7.20±0.61 6.42±0.86 Pass 
DC4 2.6 3.10±1.14 0.47 104±1.60 99.65±1.23 6.3±0.80 6±1.35 6.50±1.35 6.24±0.88 Pass 
DC5 2.6 3.12±1.12 0.46 101.5±1.20 99.84±1.04 5.6±0.10 5±1.15 4.90±0.92 4.75±1.44 Pass 
DM1 2.2 3.12±1.24 0.36 101±1.45 99.45±1.20 9.6±1.26 9±1.32 10.3±1.28 9.6±1.23 Pass 
DM2 2.2 3.12±1.24 0.21 98.6±1.55 99.24±1.43 8.6±1.29 8±1.06 9.5±1.27 8.7±1.41 Pass 
DM3 2.5 3.10±1.16 0.25 100.4±1.64 99.31±1.35 6.7±1.43 7±1.03 7.7±1.32 6.9±0.94 Pass 
DM4 2.4 3.10±1.18 0.33 101±1.53 99.14±1.13 5.2±1.36 7±1.22 6.7±1.41 6.8±0.64 Pass 
DM5 2.6 3.12±1.24 0.28 99.85±1.44 99.48±1.24 4.5±1.55 6±1.29 5.9±1.08 5.6±1.29 Pass 
DM6 2.8 3.10±1.16 0.46 99.45±1.23 99.43±1.32 4.2±1.56 4±1.35 4.0±1.21 4.6±1.31 Pass 
DCM1 2.5 3.14±1.18 0.36 99.5±1.43 99.59±0.96 8.7±1.52 8±1.03 7.7±1.32 8.2±1.23 Pass 
DCM2 2.3 3.12±1.24 0.21 100.2±1.47 99.66±0.76 3.5±1.49 6±1.22 6.7±1.41 7.0±1.41 Pass 
DCM3 2.4 3.10±1.16 0.25 98.8±1.38 99.74±0.65 4.2±1.32 5±1.29 4.9±1.08 5.3±0.94 Pass 
DCM4 2.6 3.10±1.18 0.33 101±1.40 99.83±0.88 4±1.26 4±1.35 4.4±1.21 3.7±0.64 Pass 
a =mean±percent deviation (n=20); b=mean±s. d (n=10); c= means±s. d (n=6) 
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Table 8: Effect of sublimation time of exposure on disintegration time of the tablet 
Superdisintegrant* Disintegration time (secs) 
Before sublimation Sublimation time 
1 h 3 h 5 h 
2 65  62  53  35  
3 39 35  27  18.5  
4 19  17  12  6.3  
*Percent weight based on total tablet weight 
 
 
Fig. 3: Dissolution profile of the formulations DCM1 to DCM4 tablet prepared using camphor and menthol 
 
In vivo disintegration and taste evaluation 
The values of the in vivo disintegration times are given in table 12. 
Though the differences are not much all the tablets have shown 
faster disintegration time. The human volunteers were asked to 
evaluate the taste and mouthfeel on a scale of 0–4 and the results are 
shown in table 12.  
It was observed that 3/5 volunteers reported threshold bitterness 
and 2/5 reported very slight bitterness with DC5 of the camphor 
formulation. And 4/5 volunteers reported smooth and pleasant 
mouthfeel and 1/5 reported gritty and pleasant feel with DC5 over 
other formulations. Hence, it showed better taste masking in 
formulations made with camphor. But, numbness of the tongue and 
bitterness was still persisted.  
Among the formulations made with menthol, 2/5 volunteers 
reported no bitterness and 3/5 reported threshold bitterness and 
4/5 reported smooth and pleasant mouthfeel and 1/5 reported 
gritty and pleasant feel with DM6. Hence, DM6 has better taste 
masking among formulations made with menthol. Bitterness was not 
felt but numbness still existed.  
Out of the combination formulations, with DCM2, 4/5 volunteers 
reported no bitterness and 1/5 reported threshold bitterness. 3/5 
reported smooth and pleasant mouthfeel and 2/5 reported gritty 
and pleasant mouthfeel. DCM2 showed the best taste masking with 
no bitterness or numbness observed until 1 minute. of all the 
optimized formulations, i.e., DC5, DM6 and DCM2, the formulation 
DCM2 prepared using a combination of camphor and menthol as 
sublimating agents showed the best taste masking.  
By considering all the parameters like hardness, in vitro 
disintegration time, in vivo disintegration time, wetting time, 
dispersion time, and dissolution profile of all the tablets prepared, 
the batch DCM2 prepared using a combination of the sublimating 
agents i.e. camphor and menthol can be considered for optimization. 
 
Table 9: Cumulative percent drug released vs. time form drotaverine HCl ODT using camphor (mean±SD, n=3) 
Time (min) Cumulative % drug released 
DC1 DC2 DC3 DC4 DC5 
5 86.58±1.56 81.2±1.22 93.42±0.63 99.00±0.53 99.78±1.14 
10 87.07±1.19 83.64±1.15 98.80±1.51 101.7±1.51 102.0±1.23 
15 88.53±1.37 84.62±1.44 100.1±1.22   
30 89.51±1.24 85.11±1.18    
45 90.00±1.42 86.58±1.22    
60 90.49±1.32 87.55±1.09    
90 101.3±1.41 99.83±1.53    
 
Table 10: Cumulative percent drug released vs. time form drotaverine HCl ODT using menthol (mean±SD, n=3) 
Time (min) Cumulative % drug released 
DM1 DM2 DM3 DM4 DM5 DM6 
5 98.9±1.24 98. 8±1.53 77.28±0.98 98.1±1.11 89.02±1.36 102.7±1.54 
10 99.8±1.31 100.8±1.66 100.2±1.14 99.2±1.21 96.85±1.11 102.7±1.44 
15 100.1±1.23 100.8±1.58 100.2±1.27 100.12±1.05 100.3±1.21 102.7±1.06 
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Table 11: Cumulative percent drug released vs. time form drotaverine HCl ODT using a combination of camphor and menthol (mean±SD, n=3) 
Time (min) Cumulative % drug released 
DCM1 DCM2 DCM3 DCM4 
5 98.8±0.21 100.2±1.15 95.87±1.02 89.51±1.32 
10 103.7±1.14 102.3±0.92 100.7±1.24 103.2±1.25 
15 103.7±0.94 102.3±0.94 100.7±1.16 103.2±1.38 
 
Table 12: Taste evaluation and mouthfeel of Drotaverine HCl ODT in human volunteers 
Camphor as sublimating agent 
Volunteers DC1 DC2 DC3 DC4 DC5 
T M T M T M T M T M 
I 3 - 3 + 2 + 2 + 1 + 
II 2 - 3 + 3 - 2 + 2 + 
III 3 + 2 - 3 - 3 - 2 + 
IV 3 + 3 - 3 + 2 - 1 - 
V 2 - 2 - 2 + 3 + 1 + 
Menthol as sublimating agent 
Volunteers DM1 DM2 DM3 DM4 DM5 DM6 
T M T M T M T M T M T M 
I 3 - 3 - 3 + 3 + 2 + 1 + 
II 2 - 3 + 2 + 2 + 2 + 0 + 
III 3 + 3 + 2 + 2 - 3 + 1 + 
IV 3 - 2 - 3 - 3 + 1 + 1 - 
V 2 + 2 - 2 - 1 - 1 - 0 + 
Camphor+menthol as sublimating agents 0 = No bitterness 
Volunteers DCM1 DCM2 DCM3 DCM4 1 = Threshold bitterness 
T M T M T M T M 2 = Very slight bitterness 
I 2 + 1 + 1 + 1 + 3 = Slight bitterness 
II 2 - 0 + 1 + 2 + 4 = strong bitterness 
III 1 - 0 - 2 - 2 + += Smooth and pleasant feel 
IV 2 + 0 + 2 + 2 - -= Gritty and pleasant feel 







Hari et al. 




Fig. 4: DSC thermograms a) Drotaverine HCl, b) Camphor, c) Menthol and d) optimized formulation of a combination of camphor and 
menthol DCM2 
 
Drug-excipient compatibility studies 
DSC analysis: The DSC thermograms of pure drug, sublimating 
agents camphor and menthol used in the study and DCM2 optimized 
formulation are shown in fig. 4. The DSC thermogram of pure 
drotaverine HCl exhibited a sharp endothermic peak at 215.12 °C 
corresponding to its melting point, indicating its crystalline nature. 
Camphor showed an endothermic melting peak at 177 °C and 
Menthol at 44.1 °C. 
XRD analysis 
The X-ray diffractograms of pure drug Drotaverine HCl, camphor, 
menthol and DCM2 formulation are shown in fig. 5. The diffractogram 
of Drotaverine HCl showed characteristic sharp intensity diffraction 
peaks at 2θ values of 14.5°, 22°, 44°, 65° and 77°, which reflected the 
crystalline nature of the drug. The optimized formulation (DCM2), 
showed diffraction peaks at respective 2θ values of pure drotaverine 
HCl although their relative intensities were reduced, suggesting a 
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Fig. 5: X-ray diffractograms a) Drotaverine HCl, b) Camphor, c) Menthol and d) optimized formulation of a combination of camphor and 
menthol DCM2 
 
Fourier transform infrared spectroscopy 
FTIR analysis for the pure drug, sublimating agents and formulation 
DCM2 were performed and FTIR spectra are shown in fig. 3.6 and 
the tab optimized formulations viz., with camphor DC5, with 
menthol DM6 and with camphor and menthol DCM2 were subjected 
to FTIR studies for drug excipient incompatibility studies. 
Theoretically drotaverine HCl will give principal peaks for N-H 
secondary amine (3500-3300 cm-1), for aromatic C=C stretching 
(1600-1475 cm-1), for C-H stretching (3000-2840 cm-1), for C-O 
stretching (1260-1000 cm-1) and N-H bending (1650-1580 cm-1). 
The major peaks for pure drug were 3478.19, 2979.95, 2874.45, 
2670.34, 1902.93, 1666.00, 1647.39, 1603.29, 1560.22, 1517.94, 
1503.87, 1476.76, 1432.20, 1401.87, 1395.04 and 1237.10 cm-
1
The drug solid dispersion combination did not produce a major shift 
in principal peaks of drotaverine HCl, indicating no interaction due 
to the presence of excipients. Hence, all the optimized formulations 
are compatible. Thus, FTIR spectral analysis proved the 
compatibility between drug and excipients. The FTIR spectra of pure 
drug and its combinations are presented in fig. 3.6. 
which are well in support to the theoretical prediction.  
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Fig. 6: FTIR spectra a) Drotaverine HCl, optimized formulations of b) Camphor (DC5), c) Menthol (DM6) and d) Combination of camphor 
and menthol (DCM2) 
 
CONCLUSION 
Drotaverine HCl tablets were prepared using the optimized 
superdisintegrant concentration with different ratios of drug-
subliming agent i.e. camphor or menthol or combination of both. The 
prepared tablets were exposed for different sublimation times 
keeping the exposure temperature constant at 40 °C. The 
sublimation evaluated at different temperatures, but at a higher 
temperature, the integrity of the tablet is lost due to friability. The 
sublimed tablets were evaluated for taste masking in healthy human 
volunteers and only those tablets which complied with the taste 
were further evaluated for the remaining tabletting parameters. All 
the evaluated tablets complied with the tabletting parameters and 
the majority of the formulations released the drug within 15 min. 
Among all the formulations, formulation DCM2 prepared with a 
mixture of camphor and menthol was optimized for better taste 
masking and complete drug release with good oral disintegration. 
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